Traduction de «form 10-k » (Néerlandais → Français) :

TERMINOLOGIE

autosomaal dominante spastische paraplegie type 10
paraplégie spastique autosomique dominante type 10

mozaïektrisomie 10
trisomie 10 en mosaïque

ring 10
syndrome du chromosome 10 en anneau

Kikkervirus 10
virus de la grenouille de type 10

Salmonella II, groep O:3,10
Salmonella II, groupe O:3,10

humaan echovirus 10
échovirus humain de type 10

humaan adenovirus 10
adénovirus humain 10

humaan rhinovirus 10
rhinovirus humain 10

spinocerebellaire ataxie type 10
ataxie spinocérébelleuse type 10

volledige trisomie 10
trisomie totale 10

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

10 6,3 - 10 8,3 colony forming units (CFU) levende Bordetella bronchiseptica bacteriën, stam B-C2.
Souche vivante de Bordetella bronchiseptica B-C2 : ≥ 10 6.3 - ≤ 10 8..3 unités formant colonie (UFC)

Geschat wordt dat in gewone bewaaromstandigheden (22 ± 2 °C) het aantal bacteriën meer dan 10 10 CFU (colony forming units) per zakje kan bedragen (Montag 2008).
On estime que dans les conditions de conservation habituelles (22 ± 2 °C), le nombre de bactéries peut dépasser 10 10 CFU (colony forming units) par poche (Montag, 2008).

Milieustudies tonen aan dat, in Frankrijk bijvoorbeeld, de gemeenschappelijke circuits voor warmwaterverdeling deze bacteriën herbergen in 30 à 70 % van de gevallen, met concentraties schommelend tussen 50 en 10 6 CFU/l (colony forming units per liter); meer dan 20% van de analyses uitgevoerd in verzorgingsinstellingen geven hogere aantallen dan 10 3 CFU/l.
Les études environnementales montrent que, en France par exemple, les réseaux collectifs de distribution d’eau chaude hébergent ces bactéries dans 30 à 70 % des cas, avec des concentrations de bactéries oscillant entre 50 et 10 6 UFC/l (unités formant colonie par litre); plus de 20% des analyses réalisées dans des établissements de santé ramenant des concentrations supérieures à 10 3 UFC/l.

Hoe ziet PARACODINE eruit en de inhoud van de verpakking PARACODINE tablet doet zich voor in de form van omhulde tabletten oraal in te nemen, in blisters in verpakkingen met 10 en 20 tabletten en één vepakking met 1000 tabletten.
Qu’est ce que PARACODINE et contenu de l’emballage extérieur PARACODINE comprimés est présenté sous forme de comprimés enrobés à usage oral, en plaquettes thermoformées dans des boîtes de 10, de 20 comprimés et dans une boîte de 1000 comprimés.

to pharmacovigilance and a European Organisation of 10 roadshows in Flanders, reporting form to veterinarians and retail 11 in Wallonia; a total audience of 1000 pharmacists; veterinarians was reached in this way.
to pharmacovigilance and a European Organisation of 10 roadshows in Flanders, reporting form to veterinarians and retail 11 in Wallonia; a total audience of 1000 pharmacists; veterinarians was reached in this way.